Syphilis test results report two fundamentally different kinds of information, and reading them correctly depends on knowing which type of test produced each number. One type tells you whether your body has ever encountered the bacterium that causes syphilis. The other produces a titer, a number that reflects how active the infection is right now and that your doctor uses to track whether treatment is working. The titer is the number that changes over time, and understanding what it means can save you from unnecessary worry or, conversely, alert you to a problem.
Two Types of Syphilis Tests
Every syphilis workup involves two categories of blood tests, and they answer different questions. Treponemal tests detect antibodies your immune system makes specifically against Treponema pallidum, the spiral-shaped bacterium that causes syphilis. These tests include the FTA-ABS, the TP-PA, and various automated immunoassays. A positive treponemal test usually stays positive for life, even after successful treatment. It tells you that you have been exposed to syphilis at some point, but not whether you have an active infection right now.
Nontreponemal tests, on the other hand, detect antibodies against substances released when the bacterium damages your cells. The two most common are the RPR (rapid plasma reagin) and the VDRL (Venereal Disease Research Laboratory test). These are the tests that produce titers, and their results rise and fall in rough proportion to how active the infection is. After successful treatment, nontreponemal test results decline and sometimes disappear entirely. That makes them useful for monitoring, not just diagnosis.
What a Titer Number Actually Means
When your lab report shows a result like “RPR reactive, titer 1:32,” it is telling you how many times the lab had to dilute your blood sample before the test stopped reacting. The lab takes your serum and dilutes it in a series of steps: 1:1, 1:2, 1:4, 1:8, 1:16, 1:32, 1:64, and so on. Each step doubles the dilution. The titer reported is the highest dilution at which the test is still positive. A result of 1:32 means the antibodies were detectable even after being diluted 32 times, which signals a higher antibody concentration than a result of 1:4. Accurate determination of this endpoint matters for both diagnosis and treatment monitoring, and different automated testing platforms can sometimes produce slightly different titer results for the same sample, which is why clinicians prefer to track your titers using the same test and the same lab over time.
Higher titers generally correlate with more active disease. Early primary syphilis, when the infection is still localized at the site of the initial sore, often produces relatively low titers or even negative nontreponemal results. In one study of patients by syphilis stage, about 42% of people with primary syphilis had a negative VDRL at their first visit, compared to none of those with secondary syphilis.
Secondary syphilis, when the bacterium has spread throughout the body and is provoking a strong immune response, typically generates the highest titers. Latent and tertiary stages can produce moderate or low titers. A very high titer on its own does not tell you the stage of disease, but it does indicate that the infection is provoking a substantial immune response.
Which Test Comes First
Depending on where you are tested, your lab may use one of two different testing sequences, and this affects what your initial result looks like. In the traditional algorithm, a nontreponemal test (RPR or VDRL) is run first as a screen. If that is reactive, a treponemal test confirms it. In the reverse algorithm, increasingly common in large laboratories, a treponemal test is the first screen; if positive, a nontreponemal test follows to assess disease activity. When the treponemal screen and nontreponemal follow-up disagree, a second, different treponemal test is used to resolve the discrepancy.
The practical difference matters. One large study from an Indian referral laboratory found that the reverse algorithm identified a significantly higher seroprevalence of syphilis than the traditional algorithm and that the traditional approach missed about a third of serodiagnoses.
In populations where syphilis is uncommon, however, the reverse algorithm can flag more false-reactive results on the initial treponemal screen. A direct comparison in a low-prevalence population found that reverse screening produced six false-reactive results among a thousand patients, compared to none with traditional screening, though it also caught two cases of possible latent syphilis that the traditional approach missed.
Neither algorithm is perfect. The choice often depends on the lab’s volume and automation capabilities. What matters for you as a patient is that a single positive test, whether treponemal or nontreponemal, is never the final word. Diagnosis requires both types of tests, and discordant results need further investigation. If you receive a treponemal-positive but RPR-negative result, the diagnostic picture can be genuinely uncertain. One multicenter study found that when several different treponemal tests were run on such discordant samples, the agreement among the tests ranged from only about 45% to 82%, depending on which tests were used.
Tracking Treatment With the Fourfold Drop
Once you have been treated for syphilis, the nontreponemal titer is the number that tells you whether the treatment worked. The standard benchmark is a fourfold decline, meaning the titer drops by at least two dilution steps. If your pre-treatment RPR was 1:32, a fourfold decline would bring it to 1:8 or lower. A fourfold decline in titers after treatment is considered a serologic response, the main objective evidence that the infection has been addressed.
In a study tracking patients after treatment for early syphilis, a twofold decline was already visible within one month. By three months, about 88% of participants had achieved the fourfold drop, and by six months the median decline was at least eightfold. The speed of decline depends on the stage at diagnosis. Patients with primary syphilis reached the fourfold endpoint fastest, with a median of about 37 days. For secondary syphilis, it took roughly 49 days, and for latent syphilis about 68 days. By three months after treatment, virtually all primary syphilis patients had hit the target, compared to roughly three-quarters to nine-tenths of secondary syphilis patients and a smaller proportion of those with latent disease.
Complete seroreversion, meaning the nontreponemal test turns entirely negative, is less common and takes longer. In the same study, only about 10% of patients achieved seroreversion at six months, and roughly 17% at twelve months. Many people whose treatment was fully successful never serorevert. Their titer drops to a low, stable level and stays there.
The Serofast State
If your titer does not drop by at least fourfold within the expected window, you may be described as serofast. The CDC defines this as an insufficient decline in the nontreponemal titer after the recommended treatment, assessed at 6 to 12 months for early syphilis or 12 to 24 months for late syphilis, with symptoms having resolved. Estimates suggest this happens in roughly 15 to 20% of treated patients, with some studies reporting rates as low as 5% and others as high as 41%.
Being serofast does not necessarily mean treatment failed. In many cases, the infection was cured but the immune system continues producing low levels of the antibodies that nontreponemal tests detect. The condition is more common in certain groups. Multiple studies have found that older age, particularly over 40, is a consistent risk factor, likely because the aging immune system clears these residual antibodies more slowly. A lower baseline titer at the time of treatment, such as 1:8 or below, is also associated with the serofast state, perhaps because there is less room for a measurable fourfold decline.
The challenge with the serofast state is distinguishing it from genuine treatment failure or reinfection. There is no single test that settles the question definitively. Clinicians typically consider the overall picture: whether symptoms have resolved, whether the titer has dropped at all even if not fourfold, and whether there is any ongoing exposure risk. If reinfection or treatment failure is suspected, retreatment and closer follow-up are usually recommended.
False Positives and the Prozone Phenomenon
Nontreponemal tests are not perfectly specific to syphilis. The antibodies they detect can also be triggered by other conditions, producing what is called a biological false-positive reaction. A large study characterizing these false positives found they were associated with at least 17 categories of disease and 60 individual conditions, including autoimmune disorders, certain infections, pregnancy complications, and blood disorders. The reaction was more common in women and in people at the extremes of age, both younger adults (16 to 35) and those over 80.
This is one of the reasons a reactive nontreponemal test always requires confirmation with a treponemal test. A false-positive RPR will typically show a low titer (often 1:1 or 1:2) and a negative treponemal test. If you receive a low-titer RPR result and your treponemal test is negative, the RPR result was almost certainly a false positive.
The prozone phenomenon is a different kind of false result, and it can be genuinely dangerous if unrecognized. When antibody levels are extremely high, as sometimes happens in secondary syphilis, the overwhelming amount of antibody can paradoxically prevent the clumping reaction that the test relies on to show a positive result. The result is a false negative: the test reads as nonreactive despite active, often florid infection. The fix is straightforward: the lab dilutes the sample further, which breaks the antibody excess and allows the reaction to proceed normally. If a clinician suspects syphilis but the RPR is negative, requesting diluted testing can unmask the true result.
How HIV Changes the Picture
HIV infection complicates syphilis testing and monitoring in several ways. People living with HIV tend to show a slower decline in nontreponemal titers after treatment. A retrospective study at an HIV referral hospital found that higher age, a history of previous syphilis, and a lower RPR at the time of treatment were all independently associated with a slower post-treatment decline in titers. A separate study directly comparing HIV-positive and HIV-negative patients after treatment for early syphilis found that HIV-positive participants had a significantly lower serologic response rate at 12 months: about 73% achieved the expected fourfold decline, compared to about 91% of HIV-negative patients. Among the HIV-positive group, roughly one in eight failed to reach a fourfold decline entirely, and a similar proportion actually showed a fourfold increase in titers during follow-up.
These differences do not mean treatment is less effective for people with HIV. Penicillin still works. But the serologic markers behave less predictably, which can make it harder to distinguish treatment success from failure based on titer alone. Clinicians managing syphilis in people with HIV often rely more heavily on clinical assessment alongside the numbers and may opt for more frequent monitoring.
Testing for Neurosyphilis
When syphilis is suspected to have reached the central nervous system, the standard blood tests are not enough. Neurosyphilis is diagnosed by testing cerebrospinal fluid obtained through a lumbar puncture. The CSF-VDRL is the classic test, and a positive result in the spinal fluid is highly specific for active neurosyphilis. One widely cited study found its specificity at 100%. The problem is sensitivity: the same study found the CSF-VDRL detected only about 27% of cases, meaning it misses the majority of people who actually have neurosyphilis.
Newer research has explored alternatives. The CSF-FTA-ABS test is more sensitive for screening but less specific, meaning it catches more cases but also flags some people who do not have active neurosyphilis. More recently, a biomarker called CXCL13, measured in the spinal fluid, has shown sensitivity around 78 to 83% with specificity of roughly 76 to 81%, offering a potential improvement over the traditional CSF-VDRL. The treponemal particle agglutination test, when run on spinal fluid at high titers, has also shown promise as a specific but insensitive marker. None of these tests is perfect, and diagnosing neurosyphilis often requires weighing multiple pieces of evidence together.
Rapid Tests and What They Cannot Tell You
Point-of-care syphilis tests, the kind that can produce results in minutes at a clinic visit, have expanded access to testing in settings where sending blood to a lab is impractical. These rapid tests generally detect treponemal antibodies with good sensitivity and specificity. But they share a fundamental limitation: they cannot distinguish a current, active infection from a past infection that was already treated. Because treponemal antibodies persist for life in most people, a rapid test will continue to read positive in someone who was treated and cured years ago.
Rapid tests also do not produce titers. They give a yes-or-no result. That means they are useful for initial screening but cannot replace the quantitative nontreponemal tests needed to monitor treatment. If a rapid test is positive, a full lab workup with RPR or VDRL titers is still necessary to determine whether the infection is active and to establish a baseline for tracking treatment response.
Syphilis Testing in Newborns
Interpreting syphilis test results in a newborn is uniquely tricky because antibodies from the mother cross the placenta during pregnancy. A baby born to a mother with a history of syphilis will have the mother’s antibodies circulating in their blood, which means both treponemal and nontreponemal tests can be positive even if the baby is not actually infected. The way to distinguish passively transferred maternal antibodies from the baby’s own immune response is to track titers over time. Maternal antibodies gradually decline and disappear within a few months. If the baby’s nontreponemal titer rises or fails to fall, that suggests the baby has their own active infection and needs treatment. Serial post-partum testing of antibody levels is one of the key tools for confirming or excluding congenital syphilis.
When Your Results Do Not Fit a Neat Category
Real-world syphilis serology frequently produces results that do not fit cleanly into textbook categories. A treponemal test may be positive with a nonreactive RPR, leaving you and your clinician uncertain whether you had syphilis long ago, have very early syphilis that has not yet triggered a nontreponemal response, or are seeing a false-positive treponemal result. In early primary syphilis, about 7% of patients in one study had negative results on both the VDRL and the TP-PA, with only an IgM-specific test coming back positive. At the other end of the spectrum, someone with old, treated syphilis might have a persistently positive treponemal test and a low-titer RPR that never quite disappears, creating uncertainty about whether reinfection has occurred.
The practical takeaway is that syphilis test results are best interpreted in context, never in isolation. Your titer number is meaningful primarily in comparison to your own previous titers, using the same test at the same lab. A single snapshot can point in a direction, but the trend over time is what tells the real story. If you are navigating a confusing set of results, the most productive conversation with your clinician is not about what one number means in the abstract but about what has changed since last time and what the next step should be.